<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Teprotumumab efficacy sustained after 6 months in thyroid eye disease

minute read

by Healio | February 17, 2022
placeholder

AUSTIN, Texas — In this Healio Video Perspective from the North American Neuro-Ophthalmology Society meeting, Prem Subramanian, MD, PhD, discusses the sustained efficacy of teprotumumab in patients with thyroid eye disease.

Topics: Press Coverage